A360
Key Takeaways✦ Atlas AI
01
Low-dose aspirin shows minimal to no colorectal cancer prevention benefit within 15 years, and long-term efficacy remains highly uncertain, challenging previous assumptions about its protective role.
02
The analysis highlights a critical trade-off: aspirin's uncertain, delayed cancer prevention benefits are outweighed by a clear, immediate risk of serious bleeding events like hemorrhagic stroke.
03
Clinicians must now prioritize individualized patient assessments, carefully balancing cardiovascular risk against bleeding risk to determine if low-dose aspirin is appropriate, given the new evidence.
Atlas AI
A large analysis of randomized trials suggests a daily regimen of low-dose aspirin is likely to make little to no difference in colorectal cancer risk during the first 5 to 15 years of use. Any potential benefit beyond 15 years remains uncertain, and the researchers said they were not confident in long-term estimates.
The analysis also reported time-dependent and uncertain findings on colorectal cancer mortality. It suggested aspirin use may increase deaths from colorectal cancer in the shorter term (around 5 to 10 years), while a possible reduction after 15 years was observed, though the authors noted low confidence in these conclusions.
Safety concerns
Daily aspirin use was associated with increased risks of serious extracranial hemorrhage and a probable increase in hemorrhagic stroke. The researchers emphasized that any uncertain and delayed benefit must be weighed against these harms.
What this means for patients
Given the mixed evidence, the report concludes that aspirin should not be considered a routine strategy for primary prevention of colorectal cancer based on current data. Clinical decisions should remain individualized and based on shared decision-making, balancing a patient’s cardiovascular risk profile against their risk of bleeding.
